Alphabet is looking for a huge cash injection, asking investors to put in $80 billion. The money will help build the servers and tools needed for its growing AI services, which are used by businesses and everyday users. The plan mixes three types of funding. First, the company will sell $30 billi
Disney parks have always mixed technology with entertainment—think animatronic singers and gravity-defying roller coasters. Now, a marble-carving robot is joining the team. Unlike the flashy rides guests remember, this robot works quietly in the background. It roughs out large statues from big block
Philadelphia's school district faces tough choices because of budget cuts. While city leaders debate a new tax on rideshare trips, schools are preparing for major staff shortages. One school in West Philadelphia could lose seven teachers next year. This means no art or gym classes for younger studen
A huge 15‑foot red inflatable will pop up in different spots around Dallas from June 19 to June 28. The ball, made by Kurt Perschke, has been touring cities around the world for over two decades, and this is its first stop in Texas. The plan is to place the ball each day in a new location, so people
After a major weight drop, people often wonder how to keep the new shape and avoid health problems. Some options look at surgery, hormone therapy, or everyday habits. First, a common procedure is bariatric surgery. It can reduce the stomach’s size or change how food travels, which helps people lose
SureNano Science, a Canadian biotech firm, is stepping into the fast‑growing world of GLP‑1 medicines that help people lose weight and control blood sugar. These drugs, like Ozempic and Wegovy, have already made huge profits, so big pharma is scrambling to create the next hit. SureNano wants to comp
This week isn’t packed with blockbuster events, but a few key reports could shift how investors see big tech and the broader economy. Nvidia’s results on Wednesday will likely steal the spotlight, as the company’s massive lead in AI chips makes it a test case for whether sky-high AI investments are
A Canadian company is making waves in the crowded field of metabolic disease treatments. SureNano Science, once focused on food-grade chemicals, is now shifting gears toward pharmaceuticals. Their latest move? A feature in a biotech news outlet highlighting their experimental drug, GEP-44. This pept
A fresh look at a large medical record review points to a possible link between GLP‑1 drugs and better long‑term outcomes for breast cancer patients. The research, published in a respected medical journal on May 11, examined nearly eight thousand women who received a breast cancer diagnosis betwe
Weight loss medications like Ozempic and Wegovy have helped many people shed pounds, but a hidden cost might be waiting. New research shows people often judge those who use these drugs more harshly than those who lose weight through diet and exercise. In one study, over 1, 300 participants ranked a
